论文部分内容阅读
目的:观察软肝汤联合常规药物治疗肝硬化的临床疗效,及其对患者肝功能和肝纤维化血清标志物的影响。方法:选取本院106例肝硬化患者为研究对象,按随机数字表法分为观察组与对照组各53例。对照组采用保肝、降酶及退黄等常规药物治疗,观察组在对照组用药基础上联合软肝汤治疗。3月为1疗程,2组均连续服用2疗程。观察2组临床疗效和不良反应发生情况,比较2组治疗前后肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)、白蛋白(Alb)、总胆红素(TBil)]和肝纤维化血清标志物[透明质酸(HA)、人层黏连蛋白(LN)、Ⅲ型前胶原肽(PⅢP)及Ⅳ型胶原蛋白(Ⅳ-C)]含量的变化。结果:总有效率观察组与对照组分别为86.79%和67.92%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组ALT、AST、Alb、TBil与HA、LN、PⅢP及Ⅳ-C含量比较,差异均无统计学意义(P>0.05)。治疗后,2组ALT、AST、TBil及HA、LN、PⅢP、Ⅳ-C含量均较治疗前下降(P<0.05),Alb含量均较治疗前上升(P<0.05);观察组的ALT、AST、TBil及HA、LN、PⅢP、Ⅳ-C含量均低于对照组(P<0.05),Alb含量高于对照组(P<0.05)。结论:软肝汤联合常规药物治疗肝郁脾虚、瘀血阻滞证肝硬化,效果优于单纯常规药物治疗,可有效改善患者的肝功能,且用药安全,可推广应用于临床。
Objective: To observe the clinical curative effect of Ruangan Decoction combined with routine drugs on liver cirrhosis and its influence on liver function and serum markers of hepatic fibrosis. Methods: A total of 106 cirrhotic patients in our hospital were selected as study subjects and divided into observation group (53 cases) and control group (53 cases) by random number table. The control group was treated with conventional drugs such as liver protection, enzyme-degrading and yellowing treatment. The observation group was treated with Ruan-Gan Tang on the basis of the control group. March for a course of treatment, 2 groups were taking 2 courses. The clinical efficacy and adverse reactions of the two groups were observed. The liver function indexes (ALT, AST, TB, TBil) and liver fibrosis were compared between the two groups before and after treatment (Serum HA, LN, PⅢP and Ⅳ-C) in serum were measured. Results: The total effective rate was 86.79% in the observation group and 67.92% in the control group. There was significant difference between the two groups (P <0.05). Before treatment, there was no significant difference in ALT, AST, Alb, TBil and HA, LN, PⅢP and Ⅳ-C between the two groups (P> 0.05). After treatment, the content of ALT, AST, TBil and HA, LN, PⅢP and Ⅳ-C in two groups were significantly lower than those before treatment (P <0.05) The levels of AST, TBil, HA, LN, PⅢP and Ⅳ-C were lower than those of the control group (P <0.05), and Alb levels were higher than those of the control group (P <0.05). Conclusion: RuanGan Decoction combined with routine drugs for treating liver cirrhosis with stagnation of liver, stagnation of blood and stagnation of blood stasis has better effect than simple routine drug therapy, which can effectively improve the liver function of patients and is safe to use and can be widely used in clinic.